What's Happening?
Kelun-Biotech has announced positive results from its Phase II study of sacituzumab tirumotecan (Sac-TMT) in combination with pembrolizumab for treating ovarian and cervical cancers. The study, presented at the 2026 Society of Gynecologic Oncology Annual
Meeting, showed that Sac-TMT, when used as maintenance therapy for platinum-sensitive recurrent ovarian cancer, demonstrated a median progression-free survival of 20.9 months. In the cervical cancer cohort, the combination therapy achieved an objective response rate of 51%. The study highlights Sac-TMT's potential as an effective treatment option with a manageable safety profile for patients with recurrent or metastatic gynecologic cancers.
Why It's Important?
The promising results from the Sac-TMT study could lead to new treatment options for patients with gynecologic cancers, particularly those who have limited alternatives after standard therapies. The combination of Sac-TMT with pembrolizumab may offer a new therapeutic strategy that enhances patient outcomes and extends survival rates. This development is significant as it addresses the unmet medical needs in the treatment of ovarian and cervical cancers, potentially improving the quality of life for many patients. The study's findings also support further clinical exploration and could pave the way for regulatory approvals and broader clinical use.
